Transforming cancer treatment and advancing new therapies through empowered science

Corporate Profile

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

The company’s lead product, ADCETRIS® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited is commercially available for two indications in 40 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs designed to address the unmet medical needs of people with cancer, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME and ASG-15ME. Seattle Genetics’ ADC technology is employed by a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. Across both internal and collaborator programs, there are more than 20 ADCs in clinical development using our proprietary approach to empowering antibodies.

Download Documentation  Corporate Fact Sheet
Download Documentation  2013 Annual Report
Download Documentation  2014 Proxy Statement
Investor Contact
Peggy Pinkston
Senior Director, Corporate Communications
PHONE: (425) 527-4160
FAX: (425) 527-4001
EMAIL: ppinkston@seagen.com

Media Contact
Tricia Larson
Director, Public Relations
PHONE: 425-527-4180
EMAIL: tlarson@seagen.com
Stock Quote
SGEN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$38.84
Change (%) Stock is Up 0.27 (0.70%)
Volume1,319,190
Data as of 04/17/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >
DateTitle 
04/16/14Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2014 Financial Results on May 1, 2014
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 16, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2014 financial results on Thursday, May 1, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on... 
Printer Friendly Version
04/08/14Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS® (Brentuximab Vedotin) in Key Countries
$6 Million in Milestone Payments Triggered by Achieving First Commercial Sales of ADCETRIS in Australia, South Korea and Mexico for Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 8, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive milestone payments from Takeda Pharmaceutical Company Limited (Takeda) totaling $6 million as a result... 
Printer Friendly Version
04/07/14Seattle Genetics Highlights Antibody-Drug Conjugate (ADC) Program and Technology Advances at AACR
-Seattle Genetics’ ADC Technology Featured in More Than 15 Presentations- -Multiple Preclinical Data Presentations Highlight Novel ADC Technology Advances and Support Program Development Plans- BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 7, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted research related to its antibody-drug conjugate (ADC) programs and technology in more than 15 presentations at the 105th Annual Meetin... 
Printer Friendly Version
02/27/14Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data at the 2014 Bone Marrow Transplant Tandem Meetings
-Interim Data Demonstrate 92 Percent Objective Response Rate in Ongoing Phase 1/2 Clinical Trial Evaluating ADCETRIS in Combination with Bendamustine for the Treatment of Salvage Hodgkin Lymphoma- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 27, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) today highlighted ADCETRIS (brentuximab vedotin) data at the 2014 Bone Marrow Transplant (BMT) Tandem Meetings being held February 26 to March 2, 2014, in Dallas, T... 
Printer Friendly Version
02/11/14Seattle Genetics Reports Fourth Quarter and Year 2013 Financial Results
-Total 2013 Revenues of $269.3 Million, Including $144.7 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -Data Anticipated in 2014 from ADCETRIS Phase 3 AETHERA Trial and SGN-CD19A and SGN-CD33A Pipeline Programs- -Conference call today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 11, 2014-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the fourth quart... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.